Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-08-13 00:00:00 ET · period of report 2024-08-09 · accession 0002001011-24-000071 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-13 | 2024-08-09 | LGND | Korenberg Matthew E | Pres, COO | S - Sale | $98.50 | -18.2K | 68.4K | -21% | -$1.80M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-09 | S | D | 18,245 | $98.50 | 68,368 | D | — | — |